The Breast Cancer Diagnostics Industry Is Expected to Surpass a CAGR of 7% from 2022-2032

Fact.MR predicts the global sales of breast cancer diagnostics to surpass US$ 7.9 Bn by registering a CAGR of 7% in the forecast period 2022-2032. Demand for cost-effective, technologically advanced, efficient, and accurate diagnostic solutions is anticipated to be a major trend in the industry over the decade.
Historically, from 2017 to 2021, demand for breast cancer diagnostics flourished at a CAGR of 6%. Healthcare infrastructure all over the globe took a hit when coronavirus became a global pandemic in the first quarter of 2020. Every nation had to reassess their healthcare strategies, and this resulted in major reforms all across the globe. With rising prevalence of cancer cases all over the globe, demand from the general population for effective measures to treat and diagnose breast cancer increased, and governments are focusing on extensively providing these solutions in a cost-effective manner.
Want A Detailed Understanding of Market Functioning? Request for a Sample Here -
https://www.factmr.com/connectus/sample?flag=S&rep_id=55

Breast cancer diagnostics providers are focusing on developing new instruments and devices that facilitate the early detection of breast cancer, which is vital in combating the disease effectively. Investments in research are also anticipated to see a major increase over the next ten years as focus is on treating and combating breast cancer.

Key Takeaways from the Market Study
• By test type, CEA test expected to hold more than 45% market share for breast cancer diagnostics
• By end user, hospital based labs expected to hold more than 50% market share for breast cancer diagnostics market.
• Breast cancer diagnostics industry expected to possess nearly 45% market share throughout North America.
• Breast cancer diagnostics industry expected to possess nearly 40% market share throughout Asia Pacific.
• Global market for breast cancer diagnostics to reach US$ 4 Bn by the end of 2022
"Rising number of active breast cancer cases is a major concern across the globe, and non-existence of early diagnostic solutions is a major factor influencing the landscape," says a Fact.MR analyst.
Request more information about Report Methodology -
https://www.factmr.com/connectus/sample?flag=AE&rep_id=55

Key Segments Covered in the Breast Cancer Diagnostics Report
By Test Type
• CA Tests for Breast Cancer
• BRCA Test for Breast Cancer
• ER & PR Test for Breast Cancer
• CEA Test for Breast Cancer
• KRAS Mutation Test for Breast Cancer
• HER 2 Test for Breast Cancer
• PSA Test for Breast Cancer
• EGFR Mutation Test for Breast Cancer
• Immunohistochemistry for Breast Cancer
• Others
By End User
• Hospital Associated Labs
• Independent Diagnostic Laboratories
• Cancer Research Institutes
• Others

Competitive Landscape
Scientists and experts at the RCSI University of Medicine and Health Sciences in Dublin, in a trial funded by Breast Cancer Now, are experimenting on curing secondary breast cancer, which is regarded as incurable as of now. They are studying an existing drug called talazoparib. If the trial is a success, it would change breast cancer treatment radically.
In October 2021, Allergan Aesthetics started its "The Power of You" campaign, which consists of various events and partnerships in order to create an impact in the fight against breast cancer. The campaign is expected to be carried on into the first quarter of 2022. The campaign is anticipated to help organizations in creating awareness as well as raining funds to fight breast cancer.

Key Competitors:

• Bio-Rad Laboratories Inc.
• Illumina Inc.
• Biocept Inc.
• Epigenomics AG
• AstraZeneca plc
• Myriad Genetics Inc.
• Quest Diagnostics Incorporated.
•
Interested to Procure The Data? Inquire here at -
https://www.factmr.com/checkout/55

Report Summary
The study offers comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales of breast cancer diagnostics across the globe.
A comprehensive estimate on the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of breast cancer diagnostics during the forecast period. Price point comparison by region with global average price is also considered in the study.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com

About Us:
Market research and consulting agency with a difference! That's why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range - from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we'll be an able research partner.

This release was published on openPR.